MET as a possible target for non-small-cell lung cancer. - Wikidata - wikimedia - TriplyDB

MET as a possible target for non-small-cell lung cancer.

MET as a possible target for non-small-cell lung cancer.

http://www.wikidata.org/entity/Q36660673

about

Molecular biology of lung cancer Patterns of Chromosomal Aberrations in Solid Tumors Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Expression of MET in circulating tumor cells correlates with expression in tumor tissue from advanced-stage lung cancer patients Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study.Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice.Exome sequencing deciphers a germline MET mutation in familial epidermal growth factor receptor-mutant lung cancer.Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue.Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps.Molecular pathology of lung cancer: current status and future directions In-depth proteomic analysis of six types of exudative pleural effusions for nonsmall cell lung cancer biomarker discovery.The non-coding RNAs of the H19-IGF2 imprinted loci: a focus on biological roles and therapeutic potential in Lung Cancer.Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.Biomarkers of erlotinib response in non-small cell lung cancer tumors that do not harbor the more common epidermal growth factor receptor mutations.MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated Degradation Novel Role for γ-Catenin in the Regulation of Cancer Cell Migration via the Induction of Hepatocyte Growth Factor Activator Inhibitor Type 1 (HAI-1).Prognostic value of MET protein overexpression and gene amplification in locoregionally advanced nasopharyngeal carcinoma.Nicotine enhances hepatocyte growth factor-mediated lung cancer cell migration by activating the α7 nicotine acetylcholine receptor and phosphoinositide kinase-3-dependent pathway Personalizing therapy in advanced non-small cell lung cancer Gene-expression profiles in lung adenocarcinomas related to chronic wood smoke or tobacco exposure.Clinical Challenges to Current Molecularly Targeted Therapies in Lung Cancer Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy.Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma.Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine.Predictive effect of XRCC3 Thr241Met polymorphism on platinum-based chemotherapy in lung cancer patients: meta-analysis.Radionuclide imaging of drug delivery for patient selection in targeted therapy.Prognostic and predictive biomarkers in lung cancer. A review.Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer.Targeting the oncogenic Met receptor by antibodies and gene therapy.Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.Targeting the MET pathway for potential treatment of NSCLC.Prognostic and predictive value of MET deregulation in non-small cell lung cancer Ran GTPase promotes cancer progression via Met recepto-rmediated downstream signaling.C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives.Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology.

P2860

Q24606677-E6545A8C-D6A1-4B28-8390-E611C6F750F3 Q26786127-769E9A8A-360A-4087-8163-1F027D9EAF84 Q27853167-6D86D9FB-34B1-47B3-AC85-48ACE779E3C1 Q28080730-7AF52475-63D8-4210-824E-820707C0F8C0 Q28086993-2EB2AA10-B51E-46D8-809D-444097D910AC Q28547446-D1961033-987A-4512-8F4F-B1D1AA8B507C Q33688558-2AA62CA9-F34E-4F4E-B1DC-2ED5B5E8710B Q33688612-D0B485C3-3D7D-4A6B-9AF2-84A17C1614FD Q33757138-6CB16FC1-AB38-4CD4-87F0-D3428FD072AB Q33823276-CEEC9B65-F064-4980-B684-18DB53331BF7 Q33830522-CEF85F1E-DAA1-4F41-8BEE-C97E6304DDFF Q34023414-E0D2F94B-710C-43ED-9840-CEC2B117B130 Q34163458-AFF920CB-690C-4895-A385-153DFED64E70 Q34194997-07E76C91-F519-4403-80E9-F38708CF1890 Q35325715-FCDA128F-641A-462D-8833-26A799898E12 Q35425128-1DF325AD-3717-47D0-9CF9-89F33BF7A78D Q35586700-36C682F9-9E2B-497E-AD8D-EC5B5DAE3129 Q35632206-8E1E9E11-4B78-4F6F-8928-B766E915B3DC Q35800730-907E7DB0-3D43-4D25-8F5D-2B5CEFCB2CB9 Q35860664-25528E73-2F57-4752-90A9-D900D7B6E692 Q35955290-C4381318-2509-4338-B82C-71B942DFC575 Q36502824-206F34AE-FF56-4629-B04E-120E53C37BA9 Q36811453-B1CD9A92-5EA2-4527-9065-F3F92DA63D82 Q36820341-B8DAE01A-1C14-4D72-BA17-968AB9A80AA4 Q36972377-B34EA52C-9A5B-4A83-ADC2-F8EF2B84B0C6 Q37011144-5E86EFAA-9595-4EC7-B743-3E0DF0F815BC Q37597858-3E74DA6B-53CA-48CD-ADE9-DC3D7C98C6C5 Q37634419-360BC6BC-DD6D-42C4-92F1-D1B13993A1E4 Q37721218-6D7A385F-CDA8-49CE-8FA4-C4BB9A07B007 Q38132728-500028DF-F0BF-4270-BA21-836E3E69F429 Q38176652-99D54E3E-AA5F-4C24-B79B-95400A216797 Q38178187-2817904D-B104-4C5A-BF52-FB8F15E40848 Q38213830-0E5CDD7E-EB32-43D8-BE02-EAD8FD512934 Q38216590-F7FE274B-9E1B-42AC-BE31-6974E3194AEC Q38258948-9C15B0E0-898D-46FF-B98D-42F91F8A9C9C Q38297235-F569AC55-386E-4D43-BFC5-2766AE464153 Q38493294-DCDE4E00-3D42-4D95-BECD-570BD8CDC6EE Q38742042-C189A21D-047B-4E67-BDB3-AA628CE7FA6B Q38771978-FEABC8FA-0BB2-4AA7-B8FF-37855A7A9A28 Q38869420-84643011-7B7E-4B48-8F33-582D2F99B22F

P2860

MET as a possible target for non-small-cell lung cancer.

http://www.wikidata.org/entity/Q36660673

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

MET as a possible target for non-small-cell lung cancer.

@ast

MET as a possible target for non-small-cell lung cancer.

@en

type

label

MET as a possible target for non-small-cell lung cancer.

@ast

MET as a possible target for non-small-cell lung cancer.

@en

prefLabel

MET as a possible target for non-small-cell lung cancer.

@ast

MET as a possible target for non-small-cell lung cancer.

@en

P1433

Q36660673-E74CC4FA-C71C-418E-9B53-FC94D8337D39

P1476

Q36660673-B59E376F-0A91-4301-80AF-5898EA3A7760

P2093

Q36660673-4992CDC4-5ECA-431C-8CC6-352CED499D78

P2860

Q36660673-02C2DC10-41E6-47FC-8DD9-1B227482980B

Q36660673-03975584-202B-4830-A8A9-50F0E0E07698

Q36660673-082E21C4-DCF4-4B29-9EC0-235FF6F25970

Q36660673-09712249-7ECA-454A-AC76-7F7148D0613E

Q36660673-0CCDA564-3ABE-464A-9C09-4AA63167E20B

Q36660673-0D361BB8-7803-49B3-8F1E-DEB5C0D4BE2B

Q36660673-118754AF-AEC1-4470-9EB2-245E915A80B1

Q36660673-134EF6A1-D7BB-4EB1-AEEA-A85B078B9C60

Q36660673-1BFA713F-E091-4F53-B634-A92DFFA4182C

Q36660673-1FD9CF0D-E950-4887-B8E2-90D7246278F8

P304

Q36660673-3B55F4CC-D0E4-4749-9F33-CC7BC259FB68

P31

Q36660673-D3F6A87E-EE3E-4AF7-9D57-520C25DD9381

P356

Q36660673-9AE4FCB3-D7FD-483E-A2B7-BDEDBBB02552

P407

Q36660673-FB7A1792-AB6D-4EF3-BB99-A7F515EB6820

P433

Q36660673-440C4789-42B4-4F3D-B298-EEE564DBAA42

P478

Q36660673-8944C06E-C623-4641-9B5F-34DDAB08EE05

P50

Q36660673-96151B31-EC3B-40C2-AC5C-C0E4605C6EAC

P577

Q36660673-AB556826-57F0-4FB2-800C-E332831175BF

P698

Q36660673-9FA68D86-D8EB-41A6-A7E8-81C82D8F1C2D

P932

Q36660673-759D26B9-5B66-45F7-93B6-F14B2A02AAD9

P356

JCO.2012.43.9422

P1433

Journal of Clinical Oncology

P1476

MET as a possible target for non-small-cell lung cancer.

@en

P2093

Ahad A Sadiq

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor

Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor.

ROS1 rearrangements define a unique molecular class of lung cancers.

P304

1089-1096

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2012.43.9422

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-02-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23401458

http://www.w3.org/2001/XMLSchema#string

P932

3589702

http://www.w3.org/2001/XMLSchema#string